30O Stock Overview
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
OncoTherapy Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.098 |
| 52 Week High | JP¥0.31 |
| 52 Week Low | JP¥0.09 |
| Beta | 0.42 |
| 1 Month Change | -16.95% |
| 3 Month Change | -8.41% |
| 1 Year Change | -62.88% |
| 3 Year Change | -89.11% |
| 5 Year Change | -89.78% |
| Change since IPO | -97.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 30O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.7% | -4.3% | -2.5% |
| 1Y | -62.9% | -19.4% | -0.4% |
Return vs Industry: 30O underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 30O underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 30O volatility | |
|---|---|
| 30O Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 30O's share price has been volatile over the past 3 months.
Volatility Over Time: 30O's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 60 | Junichi Shimada | www.oncotherapy.co.jp |
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
OncoTherapy Science, Inc. Fundamentals Summary
| 30O fundamental statistics | |
|---|---|
| Market cap | €25.13m |
| Earnings (TTM) | -€7.24m |
| Revenue (TTM) | €5.47m |
4.6x
P/S Ratio-3.5x
P/E RatioIs 30O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 30O income statement (TTM) | |
|---|---|
| Revenue | JP¥901.00m |
| Cost of Revenue | JP¥1.68b |
| Gross Profit | -JP¥775.00m |
| Other Expenses | JP¥417.00m |
| Earnings | -JP¥1.19b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.48 |
| Gross Margin | -86.02% |
| Net Profit Margin | -132.30% |
| Debt/Equity Ratio | 0% |
How did 30O perform over the long term?
See historical performance and comparison